^
BIOMARKER:

HRD

i
Other names: Homologous Recombination Deficiency




Show legend

Include preclinical:
Ovarian Cancer
Triple Negative Breast Cancer
Prostate Cancer
Breast Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Non Small Cell Lung Cancer
Gastric Cancer
Pancreatic Cancer
Uterine Corpus Leiomyosarcoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Melanoma
Solid Tumor
HER2 Positive Breast Cancer
Colorectal Adenocarcinoma
Mantle Cell Lymphoma
Pancreatic Ductal Adenocarcinoma
Soft Tissue Sarcoma
HER2 Negative Breast Cancer
bevacizumab
CX-5461
niraparib
bevacizumab + olaparib
olaparib
IDE161
carboplatin
talazoparib + enzalutamide capsule
rucaparib
ABT-888
CPB
tislelizumab + pamiparib
tislelizumab
bevacizumab + niraparib
olaparib + durvalumab
talazoparib
nivolumab
pembrolizumab + niraparib
nivolumab + ipilimumab
cisplatin
carboplatin + docetaxel
Immunotherapy
nivolumab + rucaparib
olaparib + temozolomide
PARP inhibitor
nivolumab + olaparib
PARG inhibitor
ABT-767
carboplatin + paclitaxel + non-pegylated liposomal doxorubicin
anlotinib + sintilimab
PD1 inhibitor
D19466
abiraterone acetate
LP-284
AZD5305
enzalutamide capsule
JPI-547
VIO-01
atezolizumab
olaparib
fam-trastuzumab deruxtecan-nxki + AZD5305
ATG-018
ifosfamide + pegylated liposomal doxorubicin